TICKERNERD
Menu
CRMDCRMDHealthcare · Biotechnology

CRMD Stock Forecast: CorMedix, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.83
−1.70% on the day

The 5 Wall Street analysts covering CorMedix, Inc. hold a median 12-month price target of $15 — +91.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$609.9M
Ticker Nerd rank
60 / 100
Median analyst target
$15
Analysts covering
5
Revenue$99.3M+149.9% y/y
Operating income$42.9M
Net income$26.0M
Free cash flow$85.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
+7.2%
YTD
−32.7%
1Y
−40.2%
From 52W high
−40.2%
From 52W low
+25.2%
$6
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CorMedix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Quality
92
Growth
88
Size
51
Revisions
50
Volatility
46
Momentum
34
Accruals
27
Issuance
12

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26CRMDHigh $19Median $15Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $13Median $15High $19

The green dot is the last close — the median target sits +91.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform$14 → $13
7 July 2026RBC CapitalMaintainsOutperform—
28 Apr 2026CitizensReiteratesMarket Outperform—
28 Apr 2026Leerink PartnersMaintainsOutperform—
28 Apr 2026RBC CapitalMaintainsOutperform—
27 Apr 2026D. Boral CapitalMaintainsBuy—
27 Apr 2026NeedhamMaintainsBuy—
5 Mar 2026NeedhamMaintainsBuy—
11 Feb 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
8 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026NeedhamMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
12 Nov 2025D. Boral CapitalMaintainsBuy—
12 Nov 2025NeedhamMaintainsBuy—
21 Oct 2025RBC CapitalMaintainsOutperform—
20 Oct 2025D. Boral CapitalUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, CorMedix, Inc. returned −40.2% against +17.5% for the S&P 500, dividends included.

CRMD vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26CRMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−13.7%
Analysts raising
2
Analysts cutting
3
Fundamentals

CorMedix, Inc. (CRMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.7×

Cheaper than 67% of US stocks

Price / sales
1.3×

Cheaper than 63% of US stocks

Price / book
1.3×

Cheaper than 63% of US stocks

EV / EBITDA
1.9×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
156.5%

Higher than 95% of US stocks

Earnings growth (YoY)
31.1%

Higher than 66% of US stocks

Gross margin
75.0%

Higher than 87% of US stocks

Operating margin
42.1%

Higher than 93% of US stocks

Net margin
40.5%

Higher than 94% of US stocks

Returns & dividend
Return on equity
54.9%

Higher than 93% of US stocks

Return on assets
24.6%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CorMedix, Inc. (CRMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CorMedix, Inc. has a market value of $609.9M and an enterprise value of $500.7M.

  • Revenue in the twelve months to 30 June 2026: $459.6M. The latest quarter grew 156.5% year on year.

  • Net income over the same four quarters: $187.2M, a 40.7% net margin.

  • Diluted earnings per share, trailing twelve months: $2.14.

  • Free cash flow in the twelve months to 30 June 2026: $250.4M.

  • Shares outstanding: 77.7M.

  • Trailing P/E: 3.7×; forward P/E: 22.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CorMedix, Inc. employs 191 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CRMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRMDCorMedix, Inc.$609.9M
60
DRUGBright Minds Biosciences, Inc.$614.9M
47
STTKShattuck Labs, Inc.$622.3M
73
OABIOmniAb, Inc.$591.7M
95
ALTAltimmune, Inc.$635.5M
25
ASMBAssembly Biosciences, Inc.$590.6M
89
ALLOAllogene Therapeutics, Inc.$589.7M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CorMedix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRMD news & analysis

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet

Zacks Investment Research · 7 Sept 2026positive

Zacks Research reported that the consensus analyst price target for CorMedix (CRMD) implies about 67.7% upside potential, while noting that this metric is not highly effective. The report also highlighted an upward trend in earnings estimate revisions, which could be a positive near-term signal for the stock.

Why it matters — This matters to CRMD watchers because it reflects analyst sentiment on the stock's upside potential and points to improving earnings estimate revisions, which are commonly watched indicators.

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

CorMedix Therapeutics announced that its senior management will participate in a fireside chat and investor meetings at the Wells Fargo 21st Annual Healthcare Conference, to be held in Boston from September 8-10, 2026.

Why it matters — This engagement gives CorMedix senior management direct exposure to investors and analysts at a major healthcare conference, which could increase visibility for the company.

CorMedix (CRMD) Upgraded to Buy: Here's Why

Zacks Investment Research · 31 Aug 2026positive

CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Zacks suggests this could drive the stock higher in the near term.

Why it matters — A positive rating upgrade signals increased confidence in CorMedix's earnings outlook, which a CRMD watcher would find relevant to the stock's near-term prospects.

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade

Zacks Investment Research · 20 Aug 2026positive

Wall Street analysts' consensus price target for CorMedix (CRMD) suggests a roughly 66% upside potential, though the article notes this metric is not highly effective. It highlights an upward trend in earnings estimate revisions as a possible near-term positive signal for the stock.

Why it matters — CRMD watchers would care because the article points to rising earnings estimate revisions as a potential near-term catalyst for the stock.

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

Zacks Investment Research · 14 Aug 2026positive

CorMedix shares rose 15% after the company reported second-quarter earnings and revenues that beat estimates, driven by solid utilization of DefenCath and contributions from the Melinta portfolio.

Why it matters — The earnings and revenue beat, aided by DefenCath utilization and Melinta contributions, signals improving commercial performance for CorMedix that CRMD watchers would note.

FAQ

Frequently asked questions about CRMD stock

What is the CRMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering CorMedix, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRMD stock a buy right now?

Of the 5 analysts covering CorMedix, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CorMedix, Inc. 60 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRMD?

As at 12 Sept 2026, CorMedix, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will CRMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +91.7% from the last close, and Ticker Nerd's factor model ranks CorMedix, Inc. 60 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRMD stock forecast for 2030?

No analyst covering CorMedix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $19 over the next 12 months.

How has CRMD stock performed over the past year?

CorMedix, Inc. returned -40.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CorMedix, Inc. do?

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

What is the latest news on CRMD?

The most recent item we track (Zacks Investment Research, 7 Sept 2026): "Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet". Zacks Research reported that the consensus analyst price target for CorMedix (CRMD) implies about 67.7% upside potential, while noting that this metric is not highly effective. The report also highlighted an upward trend in earnings estimate revisions, which could be a positive near-term signal for the stock.

Company

About CorMedix, Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through central venous catheters. The company serves healthcare providers and dialysis settings, where preventing bloodstream infections is a critical part of patient care. CorMedix also operates as a specialty pharmaceutical business with a product portfolio aimed at acute care markets and other medically important settings. Headquartered in Berkeley Heights, New Jersey, CorMedix Inc. plays a targeted role in the healthcare market by addressing complications associated with vascular access and chronic kidney failure treatment.

CEO Mr. Joseph Todisco MBA · 191 employees · United States · https://cormedix.com